In 2023, Germany led global obstructive airway diseases medicine sales with $2.69 billion, followed by Canada at $1.61 billion. Year-on-year analysis showed Canada's growth at 4.18%, significantly higher than the 3.64% witnessed by Germany. New Zealand and Costa Rica exhibited the most remarkable growth rates, at 5.32% and 7.31%, respectively. Conversely, countries like Spain, Italy, Greece, and Finland experienced negative growth rates, with Italy decreasing by 1.7%. Furthermore, a five-year CAGR analysis suggests modest growth among major nations yet highlights divergent regional performances.
Future trends in global obstructive airway disease medicine sales are poised to be influenced by aging populations, increasing prevalence of respiratory conditions, innovation in treatment options, and regional healthcare policy changes affecting pricing and reimbursement. Expected technological advancements in drug delivery systems could also drive growth in medicine sales worldwide.
Top countries in Obstructive Airway Diseases Medicine Sales by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 2,690 | 2023 | +2.07% | +3.64% | View data |
| 2 | 2 Canada | 1,610 | 2023 | +1.38% | +4.18% | View data |
| 3 | 3 Spain | 1,330 | 2023 | +1.38% | -0.34% | View data |
| 4 | 4 Italy | 1,130 | 2023 | +1.03% | -1.7% | View data |
| 5 | 5 Greece | 298.5 | 2023 | +0.64% | -1.96% | View data |
| 6 | 6 Croatia | 264.2 | 2023 | +0.61% | -0.076% | View data |
| 7 | 7 Sweden | 210.6 | 2023 | +0.29% | +0.25% | View data |
| 8 | 8 Ireland | 130.4 | 2023 | +2.27% | +1.64% | View data |
| 9 | 9 Finland | 107.8 | 2023 | +0.37% | -0.49% | View data |
| 10 | 10 New Zealand | 90.2 | 2023 | +5.13% | +5.32% | View data |
